APOBEC3B and non-small cell lung carcinoma: For example, upregulation of APOBEC3B was reported to predict worse survival in ovarian cancer 13 and associate with aggressive phenotypes in breast cancer 14, but predict better outcomes of immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC) 15.